(Irvine, CA) - Next Pharmaceuticals is launching its new patented ingredient Citri-ZTM to address two key aspects of cardiovascular health: inflammation and cholesterol. The proprietary extract is derived 100% from citrus and is standardized to not less than 30% polymethoxyflavones (PMF). “Citri-ZTM is patented (US Patent No. US 6,184,246) for its unique anti-inflammatory properties, including its ability to inhibit the pro-inflammatory cytokine TNF-α” says Bob Garrison, President and CEO of Next Pharmaceuticals. “Citri-ZTM is the only PMF material that can make an inflammation claim due to our exclusive license of the patent from the U.S. Department of Agriculture.”
Citri-Z™ offers a broader range of cardiovascular protection than other natural products for heart health. In addition to reducing inflammation, the flavones and flavonoids in the proprietary formula Citri-ZTM offer significant cardiovascular protection by reducing total cholesterol and LDL cholesterol, reducing thrombosis, inhibiting macrophage foam cell formation, improving endothelial function, and helping to maintain healthy blood pressure.
There is also evidence that the pro-inflammatory cytokine TNF-α can have a negative impact on insulin sensitivity and therefore it is expected that Citri-ZTM will improve insulin sensitivity by inhibiting TNF-α. This adds an additional benefit to cardiovascular health products by helping to maintain healthy blood sugar levels. Citri-ZTM can be incorporated into beverages and food as well as dietary supplements.
For more information on Citri-ZTM or Next’s other ingredients, please visit www.nextpharmaceuticals.com.
949.450.0203 ext. 15